Skip to main content

Table 2 Responses to neoadjuvant therapy

From: Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial

 

FAS (n = 35)

Surgery set (n = 32)

RECIST

 Complete response, n (%)

3 (8.6%)

3 (9.4%)

 Partial response, n (%)

22 (62.9%)

22 (68.7%)

 Stable disease, n (%)

7 (20.0%)

7 (21.9%)

 Progressive disease, n (%)

0

0

 Objective response rate, % (95% CI)

71.4% (53.7% to 85.4%)

78.1% (60.0% to 90.7%)

 Disease control rate, % (95% CI)

91.4% (76.9% to 98.2%)

100% (89.1% to 100.0%) *

Tumor regression grade, n (%)

 Grade 0

0

0

 Grade Ia

12 (34.3%)

12 (37.5%)

 Grade Ib

4 (11.4%)

4 (12.5%)

 Grade II

13 (37.1%)

13 (40.6%)

 Grade III

2 (5.7%)

2 (6.2%)

Pathological response, n (% [95% CI])

11 (31.4% [16.8% to 49.3%])

11 (34.4% [18.6% to 53.2%])

  1. *One-sided
  2. FAS full analysis set, RECIST Response Evaluation Criteria in Solid Tumors, CI confidence interval